• NUKED: Access is everything, with GlyTherix and Telix Pharmaceuticals

  • Sep 10 2024
  • Durée: 30 min
  • Podcast

NUKED: Access is everything, with GlyTherix and Telix Pharmaceuticals

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • In early 2023, one of the first two really big radiopharmaceutical drugs ran into a problem. Novartis' prostate cancer therapy Pluvicto, released only the year before, was suddenly in short supply, snarling up just in time treatment schedules.

    In 2024 the supply chain problem is with the isotope Actinium 225, which *everyone* wants for clinical trials. RayzeBio has been a very famous victim, delaying a clinical trial because of the shortages.

    In episode 2 of NUKED we explore where the nukes come from, and how biotechs large and small get their hands on them.

    With GlyTherix CEO Dr Brad Walsh and Telix Pharmaceuticals CEO Dr Chris Behrenbruch, we look at a potential new front in the US-China tariff war, the Russia question, and how an early stage biotech and one with a product in the market organises its nuclear material supplies.

    Support the show

    Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.
    Voir plus Voir moins
Voir plus Voir moins
activate_Holiday_promo_in_buybox_DT_T2

Ce que les auditeurs disent de NUKED: Access is everything, with GlyTherix and Telix Pharmaceuticals

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.